Depo-Medrol Classification
Yes, Depo-Medrol (methylprednisolone acetate) injection is definitively classified as an endocrinology corticosteroid. 1
Drug Classification and Mechanism
Depo-Medrol is an anti-inflammatory glucocorticoid containing methylprednisolone acetate, which is the 6-methyl derivative of prednisolone. 1
The FDA drug label explicitly describes it as a glucocorticoid for intramuscular, intra-articular, soft tissue, or intralesional injection, confirming its classification within the corticosteroid drug class. 1
Methylprednisolone acetate functions as a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, making it squarely within the endocrinology-corticosteroid category. 1
Endocrine Effects Supporting Classification
Depo-Medrol causes hypothalamic-pituitary-adrenal (HPA) axis suppression, a hallmark endocrine effect of corticosteroids that can produce reversible adrenal insufficiency and Cushing's syndrome with chronic use. 1
Even a single 40 mg injection significantly decreases serum cortisol levels within 24-72 hours, with suppression lasting up to 3 weeks after administration, demonstrating profound endocrine system impact. 2
Drug-induced secondary adrenocortical insufficiency may persist for months after discontinuation, requiring hormone replacement therapy during periods of physiological stress—a defining characteristic of endocrine corticosteroids. 1
Clinical Context
Multiple clinical guidelines reference methylprednisolone in the context of endocrine management, including treatment of hypophysitis, adrenal insufficiency, and other endocrine immune-related adverse events. 3
The drug requires careful consideration of endocrine effects including hyperglycemia, adrenal suppression, and the need for stress-dose corticosteroid coverage in patients receiving treatment. 3, 1